Efficacy and Safety of Long-Term Anticoagulation Therapy with Direct Oral Anticoagulants versus Vitamin K Antagonist in Patients with Cerebral Venous Thrombosis
Table 1.
Characteristics of studies included in the review
|
| Study (Year of Publication) |
Study Design |
Sample Size |
Location |
Age, years |
Female (%) |
Duration of Anticoagulation |
Follow-up Duration |
|
|
| Ferro et al (2019) |
Randomized Controlled Trial |
60 Warfarin60 Dabigatran |
Multicenter |
45,2 + 13.8 |
33 (55%)33 (55%) |
5.15 months |
3 months |
|
| Connor et al (2020) |
Randomized Controlled Trial |
41 Standard Anticoagulation73 Rivaroxaban |
Multicenter |
Pediatric Population (<18 years) |
18 (44%)27 (37%) |
3 months |
3 months |
|
| Khorvash et al (2021) |
Randomized Controlled Trial |
25 Warfarin25 Rivaroxaban |
Iran |
40.76 + 11.7241.20 + 11.35 |
19 (76%)17 (68%) |
3 months |
6 months |
|
| Masqood et al (2021) |
Randomized Controlled Trial |
24 Warfarin21 Rivaroxaban |
Pakistan |
27 years26 years |
19 (79%)18 (86%) |
3-12 months |
12 months |
|
|
|
